相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
H. Quach et al.
LEUKEMIA (2010)
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
Paul Richardson et al.
BLOOD (2009)
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma
Mariateresa Fulciniti et al.
BLOOD (2009)
Activation of Wnt/β-catenin signalling pathway induces chemoresistance to interferon-α/5-fluorouracil combination therapy for hepatocellular carcinoma
T. Noda et al.
BRITISH JOURNAL OF CANCER (2009)
Glycogen synthase kinase 3: more than a namesake
Geetha Vani Rayasam et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction
Gondi Kumar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism
Laure Escoubet-Lozach et al.
CANCER RESEARCH (2009)
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
Bryan T. MacDonald et al.
DEVELOPMENTAL CELL (2009)
Transcriptional activation of the β-catenin gene at the invasion front of colorectal liver metastases
Obul R. Bandapalli et al.
JOURNAL OF PATHOLOGY (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Proteasome inhibitors in the treatment of multiple myeloma
J. J. Shah et al.
LEUKEMIA (2009)
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway
M. Flahaut et al.
ONCOGENE (2009)
Shedding light on an old mystery -: Thalidomide suppresses survival pathways to induce limb defects
Juergen Knobloch et al.
CELL CYCLE (2008)
Lenalidomide for the treatment of B-cell malignancies
Asher A. Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense
Juergen Knobloch et al.
MOLECULAR PHARMACEUTICS (2008)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Sonia Vallet et al.
LEUKEMIA & LYMPHOMA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism
Masayoshi Kobune et al.
MOLECULAR CANCER THERAPEUTICS (2007)
The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells
Simona Colla et al.
BLOOD (2007)
Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway
Juergen Knobloch et al.
FASEB JOURNAL (2007)
Altered cell-cell adhesion in cisplatin-resistant human carcinoma cells:: A link between β-catenin/plakoglobin ratio and cisplatin resistance
Tamara Cimbora-Zovko et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells
Dominique Verhelle et al.
CANCER RESEARCH (2007)
Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly
AK Gandhi et al.
LEUKEMIA RESEARCH (2006)
A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia
F. De Toni et al.
ONCOGENE (2006)
A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: A potential role in the development of lytic bone disease and tumor progression in multiple myeloma
William G. Gunn et al.
STEM CELLS (2006)
Immunomodulatory analogues of thalidomide in the treatment of multiple myeloma
Revathi Suppiah et al.
CLINICAL LYMPHOMA & MYELOMA (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
Cloning of the rat β-catenin gene (Ctnnb1) promoter and its functional analysis compared with the Catnb and CTNNB1 promoters
QJ Li et al.
GENOMICS (2004)
The tumor microenvironment: focus on myeloma
WS Dalton
CANCER TREATMENT REVIEWS (2003)
Tumor formation by genetic mutations in the components of the Wnt signaling pathway
A Kikuchi
CANCER SCIENCE (2003)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism
CM Liu et al.
CELL (2002)
Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies
LA Hazlehurst et al.
CANCER AND METASTASIS REVIEWS (2001)
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A
XJ Fang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
